levodopa has been researched along with cp 101,606 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chambers, LK; Greenamyre, JT; Jaw-Tsai, SS; Menniti, FS; Steece-Collier, K | 1 |
| Ahmed, SM; Chase, TN; Dunbar, GL; Menniti, FS; Oh, JD; Wessell, RH | 1 |
| Brotchie, JM; Crossman, AR; McGuire, S; Menniti, FS; Nash, JE; Ravenscroft, P | 1 |
| Gunzler, SA; Hogarth, P; Jamerson, B; Kirchhoff, T; Krams, M; Landen, JW; Menniti, FS; Nutt, JG; Weaver, JL | 1 |
| Ba, M; Kong, M; Liu, C; Qiu, H; Zhang, H; Zhang, Y | 1 |
1 trial(s) available for levodopa and cp 101,606
| Article | Year |
|---|---|
Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.
Topics: Aged; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Dyskinesias; Excitatory Amino Acid Antagonists; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Piperidines; Severity of Illness Index | 2008 |
6 other study(ies) available for levodopa and cp 101,606
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Haloperidol; Levodopa; Macaca mulatta; Male; Parkinson Disease, Secondary; Piperidines; Rats; Rats, Inbred F344; Reaction Time; Receptors, N-Methyl-D-Aspartate | 2000 |
NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
Topics: Animals; Excitatory Amino Acid Antagonists; Functional Laterality; Levodopa; Locomotion; Male; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Rotation; Serine; Stereotyped Behavior; Sympathectomy, Chemical | 2004 |
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
Topics: Animals; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Piperidines; Range of Motion, Articular; Receptors, N-Methyl-D-Aspartate; Treatment Failure | 2004 |
NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-fyn; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Tyrosine | 2015 |